© Copyright Our Wall
The “Buffer Preparation Market, 2023-2035”
report features an extensive study of the current market landscape, market size
and future opportunities for the players engaged in the development of buffer
management systems and providing buffer manufacturing services.
Key Inclusions
§ An executive summary of the insights captured during our research,
offering a high-level view on the current state of the buffer preparation
systems market and its likely evolution in the mid-to-long term.
§ A general overview ofbuffer manufacturing, along with
information on conventional and novel methods of buffer manufacturing. In
addition, the chapter highlights the challenges associated with buffer
manufacturing, advantages of outsourcing buffer manufacturing and key
considerations while selecting an outsourcing partner. Further, it concludes
with a discussion on future perspectives in this market.
§ A detailed assessment of the overall market landscape of buffer preparation/ manufacturing systems, based on several relevant parameters,
such as type of system (whole unit and buffer tank), mode of operation
(automatic and manual), scale of operation (preclinical, clinical and
commercial), vessel fabrication material(s) (stainless steel, polymer and
others), system mobility option (mobile and stationary), feature(s) of buffer
manufacturing system (conductivity sensor, pH sensor, temperature sensor,
pressure sensor, filter and others), integrated technique(s) (chromatography,
filtration and others), buffer manufacturing process (batch and continuous),
type of buffer form(s) (conditioned buffers and diluted buffers) and
bioprocessing method (downstream and upstream). In addition, it provides an
in-depth analysis of the buffer manufacturing system providers, based on their
year of establishment, company size, location of headquarters and most active
players (in terms of number of buffer manufacturing systems offered).
§ A comprehensive product competitiveness analysis of buffer manufacturing system, based on
developer power (in terms of number of years of experience of a company) and
product competitiveness (in terms of type of system, mode of operation, scale
of operation, vessel fabrication material(s), system mobility option,
feature(s) of buffer manufacturing system, integrated technique(s), buffer
manufacturing process, buffer form(s), bioprocessing method, availability of
GMP manufacturing and single use components).
§ Elaborate profiles of key players (shortlisted based on proprietary
criterion) engaged in the development of buffer preparation systems, including
a brief overview of the company, details related to product portfolio, recent
developments and an informed future outlook.
§ A detailed assessment of the overall market landscape of buffer
manufacturing service providers, based on several relevant parameters, such as
year of establishment, company size, location of headquarters, location of
facilities, scale of operation (pre-clinical, clinical and ready-to-use buffers), buffer(s) manufactured
(acetate buffers, amino acid buffers, borate buffer, carbonate / bicarbonate
buffers, citrate buffers, potassium buffers, phosphate buffers, sodium buffers
and other buffers), buffer formulation (liquid and powder), buffer packaging
format (bags, bioprocess containers, bottles, polymer drums, and other types of
packaging), compatible biologic(s) (antibody, cell therapy, enzyme, nucleic
acid, peptide / protein, vaccine and other types of compatible biologics),
application area(s) (drug development, drug manufacturing, purification,
research and other application area), type of service (fill / finish and
packaging, formulation development, manufacturing, process development,
scale-up and other types of services)
and most active players (in terms of number of facilities and number of
services).
§ A comprehensive company competitiveness analysis of buffer
manufacturing service providers based in North America, Europe and Asia, based
on supplier power (in terms of number of years of experience of a company) and
company competitiveness (in terms of number of facilities, location of
facilities, scale of operation, type of buffer(s) provided, buffer(s)
manufactured, buffer formulation, buffer packaging format, compatible
biologic(s), application area(s), type of service and availability of GMP
manufacturing).
§ Elaborate profiles of key companies (shortlisted based on
proprietary criterion) providing buffer manufacturing services including a
brief overview of the company, key executives, company portfolio, recent
developments and an informed future outlook.
§ A detailed analysis of partnerships inked between stakeholders
engaged in this industry, since 2017, based on several relevant parameters,
such as year of partnership, type of partnership (acquisitions,
commercialization agreements, development agreements, distribution agreements,
manufacturing agreements, product development agreements, product distribution
agreements, product integration and distribution agreements, product /
technology installation agreements, research and development agreements,
service agreements, strategic alliances, and others, type of partner, company
size, most active players (in terms of the number of partnerships signed) and
regional distribution of partnership activity in this domain.
§ A detailed market
forecast, featuring analysis of the current and projected future opportunity
across key market segments (listed below)
§ Preclinical / Clinical
§ Commercial
§ Type of System
Component
§ Single-use Buffer
Mixing / Preparation Equipment
§ Reusable Buffer Mixing
/ Preparation Equipment
§ Key Geographical
Regions
§ North America
§ Europe
§ Asia-Pacific
§ Rest of the World
Key Questions Answered
§ What is the need for novel buffer manufacturing systems?
§ How many players have developed / are currently engaged in the
development of buffer manufacturing systems?
§
What
is the relative competitiveness of the buffer manufacturing systems currently
available in the market?
§
What
types of partnerships are most common in the field of buffer manufacturing
systems?
§ How many players provide services related to buffer manufacturing?
§ What is the likely growth rate (CAGR) of buffer preparation systems
market?
§ What is the current / likely future market size of buffer
manufacturing market?
§ Which region is
expected to witness the highest growth rate in the buffer manufacturing market?
To
view more details on this report, click on the link
https://www.rootsanalysis.com/reports/buffer-preparation-market.html
Learn from experts: do you know about these emerging industry
trends?
Rising Demand
for Medical Devices CROs
SARM1
Inhibitors: A Novel Approach Against Neurodegenerative Disorders
About Roots Analysis
Roots
Analysis is a global leader in the pharma / biotech market research.
Having worked with over 750 clients worldwide, including Fortune 500 companies,
start-ups, academia, venture capitalists and strategic investors for more than
a decade, we offer a highly analytical / data-driven perspective to a network
of over 450,000 senior industry stakeholders looking for credible market
insights.
Learn more about Roots Analysis
consulting services:
Roots Analysis
Consulting - the preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
The “Exosome Therapeutics Market, 2022-2040”
report features an extensive study on the current market landscape, offering an
informed opinion on the likely evolution of the exosome therapies in the
treatment of various diseases.
Key Inclusions
§ General introduction to
exosomes, types of extracellular vesicles and their origin, secretion, and type
of membrane. In addition, it provides information on the development process of
exosomes and details on applications of exosomes, mechanism of different
therapies, along with the advantages, risks associated with exosome
therapeutics and the future perspectives.
§ A detailed assessment of the current market landscape of exosome therapeutics, based on several relevant parameters, such as phase of
development (clinical and preclinical), technology platform (DeliverEXTM
platform, iPSC Platform, engEx™ Platform, mTEV Platform, PEP Exosome Technologyand others), type of payload (protein, biologics, RNA, vaccine,
antisense oligonucleotide, DNA / protein and AAV capsids), target disease
indication (s) (COVID-19, acute respiratory distress syndrome, skin
regeneration, cancer and others), therapeutic area (oncological disorders,
dermatological disorders, neurological disorders, infectious diseases, rare
disorders, autoimmune disorders and respiratory disorders and others),
biological target, route of administration (intravenous, oral, subcutaneous,
intratumoral, nasal and others), type of therapy (monotherapy and combination
therapy), combination drug, line of treatment and dosing frequency. In
addition, it provides details on the companies engaged in the development of
exosome therapeutics, along with information on their year of establishment,
company size and location of headquarters.
§ Elaborate profiles of the key players engaged in the development of
exosometherapeutics, with maximum number of therapeutic programs in
their pipeline. Each profile features a brief overview of the company, its
financial information (if available), details on its product portfolio and a
section on recent developments and an informed future outlook.
§ Elaborate drug profiles of the key therapeutics . Each profile features a brief information on
product portfolio and clinical trial information including study title, study
detail, status of trial, phase of development, trial location, patient
enrollment, study start and end date.
§ A detailed analysis of completed and ongoing clinical trials of
various exosome therapeutics, based on different parameters, such as trial
status, trial registration year, type of sponsor / collaborator, study design,
and number of patients enrolled. In addition, the chapter highlights year-wise
trend of completed and recruiting trials, age group of the patients enrolled,
active industry and non-industry players and location of the trials.
§ An in-depth analysis of academic grants that have been awarded to
various research institutes for projects related to exosome therapeutics,
during the period, 2017-2022, based on several parameters, such as year of
grant awarded, amount awarded, type of funding institute center, popular NIH
departments, support period, emerging focus area, purpose of grants, grant
activity code, local recipients, type of recipient organization study section
and type of grant application. Further, the chapter also highlights the popular
recipient organizations, (in terms of number of grants and amount awarded).
§ A detailed analysis of the global events attended by the exosome therapydevelopers, based on several relevant parameters, such as year of
event, type of event platform, location of event, emerging focus areas, active
organizers (in terms of number of events), active industry and non-industry
participants, designation of participants, affiliated department of
participants, and active speakers (in terms of number of events).
§ An analysis of the partnerships that have been established in this
domain since 2017, covering instances of research agreement, licensing
agreement, manufacturing agreement, product development and commercialization
agreement, merger / acquisition, and other relevant deals.
§ A detailed analysis of the various investments made since 2017,
including grant / award, seed financing, venture capital financing, IPOs,
secondary offering, debt financing, other equity, in companies focused on the development of
exosome therapeutics.
§ An analysis of start-ups / small companies engaged in the
development of exosome therapeutics, based on parameters, such as pipeline
strength, pipeline maturity, financial support, number of investors,
partnership activity and start-up health indexing.
§ A case study highlighting the companies engaged in offering exosome
development and manufacturing services along with the information on their year
of establishment, company size, location of headquarters, types of service(s)
offered (isolation, characterization, purification, chromatography,
engineering, targeted delivery, diagnostic biomarker, and quality control),
method of isolation, method of purification, method of characterization, method
of exosome manufacturing (engineering and targeted delivery), scale of
operation (discovery / research, pre-clinical, clinical or commercialized) and
scalability (small, mid-sized or large).
§ An in-depth analysis of exosome therapeutics that failed to
progress to later stages of clinical development, based on various relevant
parameters, such as trial status of discontinuation, target disease
indication(s), route of administration and type of sponsor.
The report also features the likely distribution of the current and
forecasted opportunity across important market segments, mentioned below:
§ Type of Therapeutic
§ Allogeneic Therapy
§ AutologousTherapy
§ Target Indication(s)
§ Degenerative Meniscal Injury
§ Dystrophic Epidermolysis Bullosa
§ Fistula Perianal
§ Retinitis Pigmentosa
§ Therapeutic Area
§ Dermatological
Disorders
§ Muscoskeletal Disorders
§ Ophthalmic Diseases
§ Rectal Disorders
§ Route of Administration
§ Fistula Tract
§ Intra-articular
§ Intra-ocular
§ Geography
§ North America
§ Europe
§ Asia-Pacific and Rest
of the World
Key Questions Answered
§ Who are the leading
industry and non-industry players engaged in the development of exosome
therapies?
§ Which are the key drugs
being developed across early and late stages of development?
§ What are the key
agendas being discussed in various global events / conferences related to
exosomes?
§ What kind of
partnership models are commonly adopted by industry stakeholders?
§ Which are the leading
funding institutes / centers supporting the research related to exosome
therapies?
§ Which geographies are
the most active in conducting clinical trials related to exosome therapies?
§ How is the current and
future market opportunity, related to exosome therapies likely to be
distributed across key market segments?
To
view more details on this report, click on the link
https://www.rootsanalysis.com/reports/exosome-therapeutics-market.html
Learn
from experts: do you know about these
emerging industry trends?
CAR-T Cell Therapies: Addressing Key
Unmet Needs Across Various Oncological Indications
Novel Cell Cytometers: Need of the
Hour
Learn from our recently published whitepaper:-
Next
Generation Biomanufacturing – The Upcoming Era of Digital Transformation
About Roots
Analysis
Roots Analysis is a global leader in the pharma / biotech
market research. Having worked with over 750 clients worldwide, including
Fortune 500 companies, start-ups, academia, venture capitalists and strategic
investors for more than a decade, we offer a highly analytical / data-driven
perspective to a network of over 450,000 senior industry stakeholders looking
for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
In pursuit of both time and cost savings, as well as to
mitigate the regulatory challenges associated with manufacturing of cell
therapy consumables, around 90% of the cell therapy developers prefer to
outsource culture media, kits, reagents and extracellular matrices to
consumable providers, which
claim to have the required expertise in order to yield high quality raw
materials.
The
financial opportunity within the cell therapy media markethas been analyzed across the following segments:
§ Type of Product
§ Media
§ Kits
§ Reagents
§ Extracellular
Matrices
§ Type of Cell Therapy
§ T-cell
Therapy
§ Stem
Cell Therapy
§ Dendritic
Cell Therapy
§ NK
Cell Therapy
§ Scale of Operation
§ Clinical
§ Commercial
§ Type of End User
§ Industry
§ Non-Industry
§ Key Geographical Regions
§ North
America
§ Europe
§ Asia-Pacific
§ Middle
East and North Africa
§ Latin
America
A
list of over 250 cell therapy developers that are anticipated to partner with
cell therapy consumables providers; these players have been shortlisted based
on several relevant parameters. The
Cell
Therapy Media,
Kits, Reagents and Surfaces Market, 2023-2035
report features the following companies, which we identified to be key players
in this domain:
§
BD Biosciences
§
Bio-Techne
§
CellGenix
§
Corning
§
Irvine
Scientific (Acquired by FUJIFILM)
§
Lonza
§
Miltenyi
Biotec
§
Sartorius
§
STEMCELL
Technologies
§
Thermo
Fisher Scientific
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape
5. Company
Competitiveness Analysis
6. Brand
Positioning of Key Industry Players
7. Company
Profiles
8. Recent
Developments and Initiatives
9. Likely
Partner Analysis for Cell Therapy surfaceProviders
10. Roots
Analysis Pricing Strategy
11. Demand
Analysis
12. Market
Forecast and Opportunity Analysis
13.
Upcoming Trends and Future Growth Opportunities
14.
Concluding Remarks
15.
Interview Transcripts
16.
Appendix 1: Tabulated Data
17.
Appendix 2: List of Companies and Organizations
To
view more details on this report, click on the link
https://www.rootsanalysis.com/reports/cell-therapy-consumables-market.html
Learn
from experts: do you know about these
emerging industry trends?
Key Trends in
Non-Viral Transfection Market
Deep Learning-based
Interoperability: Advanced Neural Networks Mimicking the Human Brain
Learn from our recently published
whitepaper: -
Next
Generation Biomanufacturing – The Upcoming Era of Digital Transformation
About Roots Analysis
Roots Analysis is a global leader in the
pharma / biotech market research. Having worked with over 750 clients
worldwide, including Fortune 500 companies, start-ups, academia, venture
capitalists and strategic investors for more than a decade, we offer a highly
analytical / data-driven perspective to a network of over 450,000 senior
industry stakeholders looking for credible market insights.
Learn more about Roots
Analysis consulting services:
Roots Analysis Consulting - the
preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
Owing to the intricacies associated
with the manufacturing processes, requirement of advanced production facilities
and the growing demand for cell therapy products, developers are actively
outsourcing certain manufacturing operations and automation technologies, in
addition to expanding their in-house capabilities.
To
view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html
Roots Analysishas done a detailed study on Cell Therapy Manufacturing Market (5th Edition),
2022-2035, covering key aspects of the industry and identifying future growth
opportunities.
To
view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html
Roots
Analysis has done a detailed study on Conjugation
and Labeling Services Market, covering
important aspects of the industry and identifying key future growth
opportunities.
Key
Market Insights
§
At present, more than 240 companies
across the globe claim to have the required capabilities to offer a
range of conjugation and labeling services for various biomolecules
§ Over
40% of the service providers offer conjugation and labeling servicesfor
both proteins and antibodies; of these, nearly 80% have the capability to
conjugate / label haptens with these biomolecules
§ In order to cater to the evolving needs of clients,
several service providers claim to be steadily expanding their existing
capabilities to enhance their respective service portfolio
§ The growing interest of stakeholders in conjugation
and labeling domain is also reflected by the increasing number of partnerships
established by various international and indigenous players
§ Over
the years, industry stakeholders and researchers have been participating in
several global events to share ideas, discuss the research outcomes and develop
a better understanding of the bioconjugationdomain
§ The
market is likely to grow at a CAGR of ~10% over the next decade, the projected
opportunity is anticipated to be well distributed across different types of
molecules, conjugates / labels and key geographical regions
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2.
EXECUTIVE SUMMARY
3.
INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Biomolecule Conjugation and
Labeling
3.3. Types of Biomolecular Conjugates and
Labels
3.4. Applications of Conjugated and Labeled
Biomolecules
3.5. Concluding Remarks
4.
CONJUGATION AND LABELING SERVICE
PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Conjugation
Servicesand Labeling Service
Providers: Overall Market Landscape
5.
COMPANY COMPETITIVENESS ANALYSIS
5.1.
Chapter Overview
5.2. Assumptions / Key Parameters
5.3.
Methodology
5.4.
Company Competitiveness Analysis
6.
COMPANY PROFILES
6.1.
Chapter Overview
6.2. AltaBioscience
6.2.1.
Company Overview
6.2.2.
Recent Developments and Future Outlook
6.3. Bachem
6.4. Bio-Synthesis
6.5. Cayman Chemical
6.6. CliniSciences
6.7. Eurogentec
6.8. GBI (formerly known as Goodwin
Biotechnology)
6.9. Mimotopes
6.10. Peptide Institute
6.11. piCHEM
7.
PARTNERSHIPS AND COLLABORATIONS
7.1.
Chapter Overview
7.2.
Partnership Models
7.3. Conjugation and Labeling Services:
Partnerships and Collaborations
8.
GLOBAL EVENT ANALYSIS
8.1.
Chapter Overview
8.2.
Scope and Methodology
8.3.
Conjugation and Labeling Services:
Global Event Analysis
8.4.
Global Events: Speaker Analysis
8.5.
Geographical Mapping of Upcoming Events
8.6.
Concluding Remarks
9.
SWOT ANALYSIS
9.1.
Chapter Overview
9.2. Conjugation and Labeling Services: SWOT
Analysis
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Forecast Methodology
10.3. Global Conjugation and Labeling Services
Market, 2023-2035
10.4. Conjugation and Labeling Services Market:
Analysis by Type of Molecule
10.5. Conjugation and Labeling Services Market:
Analysis by Type of Molecular Conjugate / Label
10.6.
Conjugation and Labeling Services
Market: Analysis by Key Geographical Regions
11. CONCLUSION
12.
EXECUTIVE INSIGHTS
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND
ORGANIZATIONS
For
additional details, please visit https://www.rootsanalysis.com/reports/conjugation-and-labeling-services-market.html
News article
Global Cell Free Expression Market
Learn
from experts: do you know about these
emerging industry trends?
At-home Self-testing: A Giant Leap Towards Transformation
in Diagnostic Sector
SARM1: A Potential
Therapeutic Target for Neurodegenerative Diseases
Learn from our recently published whitepaper: -
Next Generation Biomanufacturing – The Upcoming Era of
Digital Transformation
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech
market research. Having worked with over 750 clients worldwide, including
Fortune 500 companies, start-ups, academia, venture capitalists and strategic
investors for more than a decade, we offer a highly analytical / data-driven
perspective to a network of over 450,000 senior industry stakeholders looking
for credible market insights.
Learn more about
Roots Analysis consulting services:
Roots Analysis
Consulting - the preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415